- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 3.10 Å
- Oligo State
- homo-pentamer
- Ligands
- 5 x 7C6: (3S,3aS,9bS)-2-[(2H-1,3-benzodioxol-5-yl)sulfonyl]-3,5-dimethyl-1,2,3,3a,5,9b-hexahydro-4H-pyrrolo[3,4-c][1,6]naphthyridin-4-one(Non-covalent)
- 5 x GLY: GLYCINE(Non-covalent)
GLY.2: 8 residues within 4Å:- Chain A: F.159, Y.202, T.204, F.207
- Chain B: F.63, R.65, L.117, S.129
4 PLIP interactions:1 interactions with chain A, 3 interactions with chain B- Hydrogen bonds: A:F.159, B:S.129, B:S.129
- Salt bridges: B:R.65
GLY.6: 8 residues within 4Å:- Chain B: F.159, Y.202, T.204, F.207
- Chain C: F.63, R.65, L.117, S.129
3 PLIP interactions:2 interactions with chain C, 1 interactions with chain B- Hydrogen bonds: C:S.129, B:F.159
- Salt bridges: C:R.65
GLY.10: 7 residues within 4Å:- Chain D: F.159, Y.202, T.204
- Chain E: F.63, R.65, L.117, S.129
5 PLIP interactions:2 interactions with chain E, 3 interactions with chain D- Hydrogen bonds: E:S.129, D:F.159, D:T.204, D:T.204
- Salt bridges: E:R.65
GLY.14: 8 residues within 4Å:- Chain C: F.159, Y.202, T.204, F.207
- Chain D: F.63, R.65, L.117, S.129
3 PLIP interactions:2 interactions with chain D, 1 interactions with chain C- Hydrogen bonds: D:S.129, C:T.204
- Salt bridges: D:R.65
GLY.18: 7 residues within 4Å:- Chain A: F.63, R.65, L.117, S.129
- Chain E: F.159, Y.202, T.204
6 PLIP interactions:2 interactions with chain E, 2 interactions with chain A, 2 Ligand-Ligand interactions- Hydrogen bonds: E:F.159, E:T.204, A:S.129, G.18, G.18
- Salt bridges: A:R.65
- 5 x IVM: (2aE,4E,5'S,6S,6'R,7S,8E,11R,13R,15S,17aR,20R,20aR,20bS)-6'-[(2S)-butan-2-yl]-20,20b-dihydroxy-5',6,8,19-tetramethyl-17 -oxo-3',4',5',6,6',10,11,14,15,17,17a,20,20a,20b-tetradecahydro-2H,7H-spiro[11,15-methanofuro[4,3,2-pq][2,6]benzodioxacy clooctadecine-13,2'-pyran]-7-yl 2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)-3-O-methyl-alpha-L-arabino-hexopyranoside(Non-covalent)
IVM.3: 15 residues within 4Å:- Chain A: T.264, S.267, S.268, S.278, V.280, D.284, A.288, L.291, F.295
- Chain B: I.225, Q.226, I.229, P.230, L.233, I.236
10 PLIP interactions:5 interactions with chain B, 5 interactions with chain A- Hydrophobic interactions: B:I.229, B:P.230, B:I.236, A:V.280, A:A.288, A:L.291, A:F.295
- Hydrogen bonds: B:I.225, B:Q.226, A:S.267
IVM.7: 19 residues within 4Å:- Chain B: T.264, S.267, S.268, S.278, Y.279, V.280, D.284, A.288, L.291, F.295
- Chain C: G.221, L.224, I.225, Q.226, I.229, P.230, L.232, L.233, I.236
11 PLIP interactions:4 interactions with chain B, 7 interactions with chain C- Hydrophobic interactions: B:V.280, B:L.291, B:F.295, C:I.225, C:I.229, C:P.230, C:L.233, C:I.236
- Hydrogen bonds: B:S.267, C:I.225, C:Q.226
IVM.11: 14 residues within 4Å:- Chain C: T.264, S.267, S.278, V.280, D.284, A.288, L.291, F.295
- Chain D: I.225, Q.226, I.229, P.230, L.232, L.233
11 PLIP interactions:4 interactions with chain C, 7 interactions with chain D- Hydrophobic interactions: C:V.280, C:L.291, C:F.295, D:I.225, D:I.229, D:P.230, D:L.232, D:L.233
- Hydrogen bonds: C:S.267, D:I.225, D:Q.226
IVM.15: 12 residues within 4Å:- Chain D: T.264, S.267, V.280, D.284, A.288, L.291, F.295
- Chain E: I.225, Q.226, I.229, P.230, L.233
9 PLIP interactions:5 interactions with chain E, 4 interactions with chain D- Hydrophobic interactions: E:I.225, E:P.230, E:L.233, D:V.280, D:L.291, D:F.295
- Hydrogen bonds: E:I.225, E:Q.226, D:S.267
IVM.19: 15 residues within 4Å:- Chain A: I.225, Q.226, I.229, P.230, L.232, L.233, I.236
- Chain E: T.264, S.267, S.268, V.280, D.284, A.288, L.291, F.295
10 PLIP interactions:5 interactions with chain E, 5 interactions with chain A- Hydrophobic interactions: E:V.280, E:A.288, E:L.291, E:F.295, A:P.230, A:L.232, A:I.236
- Hydrogen bonds: E:S.267, A:I.225, A:Q.226
- 5 x ZN: ZINC ION(Non-covalent)
ZN.4: 3 residues within 4Å:- Chain A: E.192, D.194, H.215
3 PLIP interactions:3 interactions with chain A- Metal complexes: A:D.194, A:D.194, A:H.215
ZN.8: 3 residues within 4Å:- Chain B: E.192, D.194, H.215
2 PLIP interactions:2 interactions with chain B- Metal complexes: B:E.192, B:D.194
ZN.12: 3 residues within 4Å:- Chain C: E.192, D.194, H.215
3 PLIP interactions:3 interactions with chain C- Metal complexes: C:E.192, C:D.194, C:H.215
ZN.16: 3 residues within 4Å:- Chain D: E.192, D.194, H.215
2 PLIP interactions:2 interactions with chain D- Metal complexes: D:E.192, D:D.194
ZN.20: 3 residues within 4Å:- Chain E: E.192, D.194, H.215
3 PLIP interactions:3 interactions with chain E- Metal complexes: E:E.192, E:D.194, E:H.215
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Huang, X. et al., Crystal Structures of Human GlyR alpha 3 Bound to Ivermectin. Structure (2017)
- Release Date
- 2017-05-24
- Peptides
- Glycine receptor subunit alpha-3: ABCDE
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
DE
E - Membrane
-
We predict this structure to be a membrane protein.
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 3.10 Å
- Oligo State
- homo-pentamer
- Ligands
- 5 x 7C6: (3S,3aS,9bS)-2-[(2H-1,3-benzodioxol-5-yl)sulfonyl]-3,5-dimethyl-1,2,3,3a,5,9b-hexahydro-4H-pyrrolo[3,4-c][1,6]naphthyridin-4-one(Non-covalent)
- 5 x GLY: GLYCINE(Non-covalent)
- 5 x IVM: (2aE,4E,5'S,6S,6'R,7S,8E,11R,13R,15S,17aR,20R,20aR,20bS)-6'-[(2S)-butan-2-yl]-20,20b-dihydroxy-5',6,8,19-tetramethyl-17 -oxo-3',4',5',6,6',10,11,14,15,17,17a,20,20a,20b-tetradecahydro-2H,7H-spiro[11,15-methanofuro[4,3,2-pq][2,6]benzodioxacy clooctadecine-13,2'-pyran]-7-yl 2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)-3-O-methyl-alpha-L-arabino-hexopyranoside(Non-covalent)
- 5 x ZN: ZINC ION(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Huang, X. et al., Crystal Structures of Human GlyR alpha 3 Bound to Ivermectin. Structure (2017)
- Release Date
- 2017-05-24
- Peptides
- Glycine receptor subunit alpha-3: ABCDE
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
DE
E - Membrane
-
We predict this structure to be a membrane protein.